Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is expected to see continued growth in subscribers and revenue, with a focus on international expansion. However, there are concerns about margin and investment challenges, as well as potential regulatory risks and competition in the GLP-1 market. The recent partnership with Novo Nordisk and strong outlook for revenue by 2030 provide a positive outlook, but the company must carefully manage economics and customer retention to sustain growth and justify investments.

Bears say

Hims & Hers Health is facing a number of challenges and concerns that are contributing to a negative outlook from financial analysts. These concerns include slow revenue growth, declining margins, competition from larger players and venture-backed startups, and the potential impact of tighter regulations on its compounding businesses. Additionally, while its weight loss segment is currently a key driver of growth, there are risks associated with entering the competitive GLP-1 market. While the recent partnership with Novo Nordisk may provide some relief from these challenges, there are still uncertainties and risks ahead for Hims & Hers Health.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.